Cure8 news brief
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so it signals development progress but not clinical proof of benefit yet.
Patients with Crohn’s disease, clinicians following emerging biologic therapies, and researchers interested in DR3/immune‑pathway targeted drug development.
Shattuck’s SL‑325 is a novel monoclonal/bispecific DR3 blocking antibody being developed for Crohn’s disease and other immune-mediated conditions. The company reported a Phase 1 first‑in‑human study in healthy participants that assessed safety, tolerability, PK, immunogenicity, and PD, and said the candidate was well tolerated across a range of doses.
Based on those results, Shattuck expects to begin a Phase 2 trial in Crohn’s disease in the third quarter of 2026. This article is a finance-focused summary, so it does not provide trial design details, timelines beyond the planned start quarter, or patient eligibility and endpoints.
It also mentions other companies and programs (Sensei, Alumis) with unrelated indications and milestones. If you’re tracking potential new Crohn’s treatments, SL‑325 is one to watch for Phase 2 enrollment updates and later efficacy/safety results.
For treatment decisions, rely on your care team and peer‑reviewed clinical data rather than early company announcements.
This is a business/market news roundup — details are limited. The Phase 1 results referenced were in healthy volunteers, not patients, and the article does not report efficacy data. Early trial starts are milestones but do not guarantee later success.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early clinical data suggest PALI-2108 may affect both inflammation and fibrosis in Crohn’s disease and shows biomarker changes (like fecal calprotectin) that could matter to people monitoring disease activity.
TREMFYA (guselkumab) is an IL-23 inhibitor being studied for ulcerative colitis and Crohn's disease; new trial data could affect future treatment options. For people with IBD, drug-development news may indicate upcoming...
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
